Evidence map›Paper›PMID 42481859›Full record

ArticleInternational journal of clinical oncology2026

Excitation-light blocking filter for photoimmunotherapy tailored to the ORBEYE 4K 3D exoscope.

Ryuhei Okada, Hideki Kanebako, Ryosuke Takahashi, Taisei Nagahisa, Shigeru Kondo, Takaaki Sato, Tomoaki Asamori, Kazuchika Ohno, Michiko Machida, Takahiro Asakage

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ryuhei OkadaDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan. okadoto@md.isct.ac.jp.ORCID http://orcid.org/0000-0003-3589-5054
Hideki KanebakoRakuten Medical K.K., Tokyo, Japan.
Ryosuke TakahashiDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.
Taisei NagahisaDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.
Shigeru KondoDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.
Takaaki SatoDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.
Tomoaki AsamoriDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.
Kazuchika OhnoDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.
Michiko MachidaRakuten Medical K.K., Tokyo, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Institute of Science Tokyo, 1-5-45, Yushima, Bunkyo, Tokyo, 113-8519, Japan.

Funding

Japan Society for the Promotion of Science London 23K14642
6 · The paper itself

Abstract

backgroundPhotoimmunotherapy, which involves combining targeted antibodies with light-activatable dyes such as IRDye700DX (IR700), is an emerging cancer treatment modality. Cetuximab-based photoimmunotherapy is approved for the treatment of unresectable head and neck cancer and has been covered by the national health insurance in Japan since 2021. Use of conventional ceiling surgical lighting during photoimmunotherapy is problematic due to concerns about potential cytotoxic effects.

methodsTo ensure safe surgical application, we developed a custom short-pass filter for the ORBEYE surgical exoscope to block IR700 excitation light. The filter's impact on the color tone was evaluated using human skin and a color checker, while that on the cytotoxicity was assessed in vitro using cetuximab-IR700 and an HSC-3 cell line. The clinical feasibility of using this filter was tested in six patients who underwent short surgical procedures (e.g., tracheostomy, arterial ligation) during photoimmunotherapy.

resultsRecalibrating the white balance after filter placement preserved the natural color tones. In vitro, the filter neutralized the significant cytotoxicity observed under the ORBEYE light. Clinically, the filter could be used safely in all cases with no evidence of postoperative skin damage.

conclusionThis filter system enhances the safety and feasibility of surgical procedures during photoimmunotherapy.

Indexed as

Head and Neck NeoplasmsImmunotherapyIndolesPhototherapyAgedCell Line, TumorCetuximabFemaleHumansLightMaleMiddle AgedOrganosilicon CompoundsPhotosensitizing AgentsCetuximabIndolesIRDye700DX N-hydroxysuccinimide esterOrganosilicon CompoundsPhotosensitizing AgentsAlluminoxHead and neck cancerIR700Photodynamic therapyPhotoimmunotherapy

Identifiers

PMID42481859
PMCPMC13615148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.